123 related articles for article (PubMed ID: 15245609)
1. The use of gallium-67 scintigraphy to monitor tumor response rates and predict long-term clinical outcome in patients with lymphoma.
Tuli MM; Al-Shemmari SH; Ameen RM; Al-Muhanadi S; Al-Huda FA; Ballani N; Khoshi M; Al-Enezi F; Bajciova V; Mottl H
Clin Lymphoma; 2004 Jun; 5(1):56-61. PubMed ID: 15245609
[TBL] [Abstract][Full Text] [Related]
2. Early restaging gallium scans predict outcome in poor-prognosis patients with aggressive non-Hodgkin's lymphoma treated with high-dose CHOP chemotherapy.
Janicek M; Kaplan W; Neuberg D; Canellos GP; Shulman LN; Shipp MA
J Clin Oncol; 1997 Apr; 15(4):1631-7. PubMed ID: 9193363
[TBL] [Abstract][Full Text] [Related]
3. Gallium scan in adolescents and children with Hodgkin's disease (HD). Treatment response assessment and prognostic value.
Castellani MR; Cefalo G; Terenziani M; Aliberti G; Maccauro M; Alessi A; Villano C; Bombardieri E
Q J Nucl Med; 2003 Mar; 47(1):22-30. PubMed ID: 12714951
[TBL] [Abstract][Full Text] [Related]
4. Bone lymphoma: 67Ga scintigraphy and CT for prediction of outcome after treatment.
Israel O; Mekel M; Bar-Shalom R; Epelbaum R; Hermony N; Haim N; Dann EJ; Frenkel A; Ben-Arush M; Gaitini D
J Nucl Med; 2002 Oct; 43(10):1295-303. PubMed ID: 12368366
[TBL] [Abstract][Full Text] [Related]
5. Clinical pretreatment risk factors and Ga-67 scintigraphy early during treatment for prediction of outcome of patients with aggressive non-Hodgkin lymphoma.
Israel O; Mor M; Epelbaum R; Frenkel A; Haim N; Dann EJ; Gaitini D; Bar-Shalom R; Kolodny GM; Front D
Cancer; 2002 Feb; 94(4):873-8. PubMed ID: 11920453
[TBL] [Abstract][Full Text] [Related]
6. Lymphoma: predictive value of Ga-67 scintigraphy after treatment.
Front D; Ben-Haim S; Israel O; Epelbaum R; Haim N; Even-Sapir E; Kolodny GM; Robinson E
Radiology; 1992 Feb; 182(2):359-63. PubMed ID: 1732950
[TBL] [Abstract][Full Text] [Related]
7. Comparison of technetium-99m tetrofosmin and gallium-67 citrate scintigraphy for detecting malignant lymphoma.
Yang CC; Sun SS; Lin CC; Kao CH; Lee CC
Anticancer Res; 2001; 21(5):3695-8. PubMed ID: 11848545
[TBL] [Abstract][Full Text] [Related]
8. The continuing clinical role of gallium 67 scintigraphy in the age of receptor imaging.
Front D; Bar-Shalom R; Israel O
Semin Nucl Med; 1997 Jan; 27(1):68-74. PubMed ID: 9122725
[TBL] [Abstract][Full Text] [Related]
9. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease.
Kostakoglu L; Coleman M; Leonard JP; Kuji I; Zoe H; Goldsmith SJ
J Nucl Med; 2002 Aug; 43(8):1018-27. PubMed ID: 12163626
[TBL] [Abstract][Full Text] [Related]
10. Aggressive non-Hodgkin lymphoma: early prediction of outcome with 67Ga scintigraphy.
Front D; Bar-Shalom R; Mor M; Haim N; Epelbaum R; Frenkel A; Gaitini D; Kolodny GM; Israel O
Radiology; 2000 Jan; 214(1):253-7. PubMed ID: 10644133
[TBL] [Abstract][Full Text] [Related]
11. Comparison of magnetic resonance imaging and (67)gallium scintigraphy in the evaluation of posttherapeutic residual mediastinal mass in the patients with Hodgkin's lymphoma.
Herman M; Paucek B; Raida L; Myslivecek M; Zapletalová J
Eur J Radiol; 2007 Dec; 64(3):432-8. PubMed ID: 17478069
[TBL] [Abstract][Full Text] [Related]
12. Comparison of 18F-fluoro-2-deoxyglucose positron emission tomography and gallium-67 citrate scintigraphy for detecting malignant lymphoma.
Shen YY; Kao A; Yen RF
Oncol Rep; 2002; 9(2):321-5. PubMed ID: 11836600
[TBL] [Abstract][Full Text] [Related]
13. Differentiation of low-grade gastric MALT lymphoma and high-grade gastric MALT lymphoma: the clinical value of Ga-67 citrate scintigraphy--a pilot study.
Hsu CH; Sun SS; Kao CH; Lin CC; Lee CC
Cancer Invest; 2002; 20(7-8):939-43. PubMed ID: 12449725
[TBL] [Abstract][Full Text] [Related]
14. Role of serial quantitative gallium-67 tumor uptake in assessing response rates for chemotherapy in lymphoma patients.
Ballani NS; Khan HA; Al-Mohannadi SH; Al-Huda FA; Usmani S; Tuli MM; Al-Shemmari SH; Al-Sawagh HF; Al-Enezi FH
Nucl Med Commun; 2008 Jun; 29(6):527-34. PubMed ID: 18458599
[TBL] [Abstract][Full Text] [Related]
15. Gallium-67 scintigraphy evaluation of therapy in non-Hodgkin's lymphoma.
Gasparini M; Bombardieri E; Castellani M; Tondini C; Maffioli L; Devizzi L; Gerundini P
J Nucl Med; 1998 Sep; 39(9):1586-90. PubMed ID: 9744348
[TBL] [Abstract][Full Text] [Related]
16. Agreement rates among single photon emission computed tomography using gallium-67, computed axial tomography and lymphangiography for Hodgkin disease and correlation of image findings with clinical outcome.
Ha CS; Choe JG; Kong JS; Allen PK; Oh YK; Cox JD; Edmund E
Cancer; 2000 Sep; 89(6):1371-9. PubMed ID: 11002233
[TBL] [Abstract][Full Text] [Related]
17. Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP
Borchmann P; Haverkamp H; Lohri A; Mey U; Kreissl S; Greil R; Markova J; Feuring-Buske M; Meissner J; Dührsen U; Ostermann H; Keller U; Maschmeyer G; Kuhnert G; Dietlein M; Kobe C; Eich H; Baues C; Stein H; Fuchs M; Diehl V; Engert A
Lancet Oncol; 2017 Apr; 18(4):454-463. PubMed ID: 28236583
[TBL] [Abstract][Full Text] [Related]
18. Gallium-67 scans as an adjunct to computed tomography scans for the assessment of a residual mediastinal mass in pediatric patients with Hodgkin's disease. A Pediatric Oncology Group study.
Weiner M; Leventhal B; Cantor A; Wimmer R; Berry DL; Cook B; Ducos R
Cancer; 1991 Dec; 68(11):2478-80. PubMed ID: 1933785
[TBL] [Abstract][Full Text] [Related]
19. Hodgkin's disease: prognostic role of gallium scintigraphy after chemotherapy.
Brenot-Rossi I; Bouabdallah R; Di Stefano D; Bardou VJ; Stoppa AM; Camerlo J; Sauvan R; Gastaut JA; Pasquier J
Eur J Nucl Med; 2001 Oct; 28(10):1482-8. PubMed ID: 11685490
[TBL] [Abstract][Full Text] [Related]
20. Suppressed hepatic uptake of Ga-67 after chemotherapy for non-Hodgkin's lymphoma.
Thakore K; Patel S; Luttrell CA; Haymon ML; Ward K; Smith J
Clin Nucl Med; 1996 Jan; 21(1):65-6. PubMed ID: 8741895
[No Abstract] [Full Text] [Related]
[Next] [New Search]
